The rise of the “Ozempic face” ##
The GLP-1 class of drugs helps to lose weight by mimicking a hormone that makes you feel full. User numbers are skyrocketing: a Gallup poll shows 11% of U.S. adults will be using these drugs for weight loss in 2026, up from 3% two years ago. In addition to digestive side effects, the rapid weight loss they deliver can cause sagging facial and body skin – a change that has given rise to the popular term “Ozempic face.”
When you lose a large amount of weight in four to six months, it can actually affect the volume of your face. | Michael Somenek
Somenek, a Washington-based facial plastic surgeon and associate professor of clinical medicine at George Washington University, said last year that he had seen a sharp increase in requests for treatment from patients using GLP-1. A 2024 report by Medical Insight found that 53% of U.S. cosmetic clinics expect to see new patients prescribed weight-loss drugs, and 43% believe there will be increased demand for therapies to address changes on the face related to these drugs.
The “giants” make-up entered the game ##
With Pfizer estimating that the obesity-treatment drug market could reach $150 billion a year by 2030, cosmetics and aesthetic medicine companies are seeing big opportunities.
















